Cargando…

Differences in brain pathological changes between rotenone and 6-hydroxydopamine Parkinson’s disease models

Rotenone and 6-hydroxydopamine are two drugs commonly used to generate Parkinson’s disease animal models. They not only achieve degenerative changes of dopaminergic neurons in the substantia nigra, but also satisfy the requirements for iron deposition. However, few studies have compared the characte...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Lan-Xiang, Du, Dan, Wang, Zhan-Qiu, Fang, Yuan, Zheng, Tao, Dong, Yan-Chao, Shi, Qing-Lei, Zhao, Min, Xiao, Fang, Du, Juan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medknow Publications & Media Pvt Ltd 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6065241/ https://www.ncbi.nlm.nih.gov/pubmed/30028338 http://dx.doi.org/10.4103/1673-5374.235076

Ejemplares similares

Achyranthes bidentata polypeptide protects dopaminergic neurons from apoptosis induced by rotenone and 6-hydroxydopamine
por: Peng, Su, et al.
Publicado: (2018)

Distinct Effects of Rotenone, 1-methyl-4-phenylpyridinium and 6-hydroxydopamine on Cellular Bioenergetics and Cell Death
por: Giordano, Samantha, et al.
Publicado: (2012)

Detecting dopaminergic neuronal degeneration using diffusion tensor imaging in a rotenone-induced rat model of Parkinson's disease: fractional anisotropy and mean diffusivity values
por: Liu, Lan-xiang, et al.
Publicado: (2017)

β-Cells Different Vulnerability to the Parkinsonian Neurotoxins Rotenone, 1-Methyl-4-phenylpyridinium (MPP(+)) and 6-Hydroxydopamine (6-OHDA)
por: Carli, Marco, et al.
Publicado: (2021)

Transcriptome profiling of five brain regions in a 6‐hydroxydopamine rat model of Parkinson’s disease
por: Lyu, Ying, et al.
Publicado: (2021)

Evaluation of 6-Hydroxydopamine and Rotenone In Vitro Neurotoxicity on Differentiated SH-SY5Y Cells Using Applied Computational Statistics
por: Simões, Rui F., et al.
Publicado: (2022)

Omarigliptin Mitigates 6-Hydroxydopamine- or Rotenone-Induced Oxidative Toxicity in PC12 Cells by Antioxidant, Anti-Inflammatory, and Anti-Apoptotic Actions
por: Gouda, Noha A., et al.
Publicado: (2022)

Rotenone, Paraquat, and Parkinson’s Disease
por: Tanner, Caroline M., et al.
Publicado: (2011)

Progression of Parkinson's Disease Pathology Is Reproduced by Intragastric Administration of Rotenone in Mice
por: Pan-Montojo, Francisco, et al.
Publicado: (2010)

Characterization of the resting-state brain network topology in the 6-hydroxydopamine rat model of Parkinson’s disease
por: Westphal, Robert, et al.
Publicado: (2017)

Neuroprotective Effect of Pseudoginsenoside-F11 on a Rat Model of Parkinson's Disease Induced by 6-Hydroxydopamine
por: Wang, Jian Yu, et al.
Publicado: (2013)

Mitochondrial Dynamics and Mitophagy in the 6-Hydroxydopamine Preclinical Model of Parkinson's Disease
por: Galindo, Maria F., et al.
Publicado: (2012)

Parkinson’s Disease and the Heart: Studying Cardiac Metabolism in the 6-Hydroxydopamine Model
por: Silva da Fonsêca, Victor, et al.
Publicado: (2023)

Intranasal delivery of mitochondria for treatment of Parkinson’s Disease model rats lesioned with 6-hydroxydopamine
por: Chang, Jui-Chih, et al.
Publicado: (2021)

Cardiac Dysregulation and Myocardial Injury in a 6-Hydroxydopamine-Induced Rat Model of Sympathetic Denervation
por: Jiang, Yue-Hua, et al.
Publicado: (2015)

Time-course behavioral features are correlated with Parkinson's disease-associated pathology in a 6-hydroxydopamine hemiparkinsonian rat model
por: Su, Rui-Jun, et al.
Publicado: (2018)

Lesioning of the Striatum Reverses Motor Asymmetry in the 6-Hydroxydopamine Rodent Model of Parkinsonism
por: Friehs, G. M., et al.
Publicado: (1991)

Upregulation of Cysteine Protease Cathepsin X in the 6-Hydroxydopamine Model of Parkinson’s Disease
por: Pišlar, Anja, et al.
Publicado: (2018)

Paeonol Protection Against Intrastriatal 6-Hydroxydopamine Rat Model of Parkinson’s Disease
por: Ghalami, Jamileh, et al.
Publicado: (2021)

Highly Potent, Selective, and Competitive Indole-Based MAO-B Inhibitors Protect PC12 Cells against 6-Hydroxydopamine- and Rotenone-Induced Oxidative Stress
por: Elsherbeny, Mohamed H., et al.
Publicado: (2021)

Lipid profiles in the cerebrospinal fluid of rats with 6-hydroxydopamine-induced lesions as a model of Parkinson’s disease
por: Qiu, Jiewen, et al.
Publicado: (2023)

Stereotaxical Infusion of Rotenone: A Reliable Rodent Model for Parkinson's Disease
por: Xiong, Nian, et al.
Publicado: (2009)

Ellagic Acid Protects the Brain Against 6-Hydroxydopamine Induced Neuroinflammation in a Rat Model of Parkinson’s Disease
por: Farbood, Yaghoob, et al.
Publicado: (2015)

The role of autophagy in Parkinson's disease: rotenone-based modeling
por: Xiong, Nian, et al.
Publicado: (2013)

Activin A Protects Midbrain Neurons in the 6-Hydroxydopamine Mouse Model of Parkinson’s Disease
por: Stayte, Sandy, et al.
Publicado: (2015)

Metabolomics and biochemical alterations caused by pleiotrophin in the 6-hydroxydopamine mouse model of Parkinson’s disease
por: Gramage, Esther, et al.
Publicado: (2022)

Therapeutic effects of baicalein on rotenone-induced Parkinson’s disease through protecting mitochondrial function and biogenesis
por: Zhang, Xue, et al.
Publicado: (2017)

The dosage of curcumin to alleviate movement symptoms in a 6-hydroxydopamine-induced Parkinson's disease rat model
por: Liu, Xiaoyu, et al.
Publicado: (2023)

Interactions of CaMKII with dopamine D2 receptors: roles in levodopa-induced dyskinesia in 6-hydroxydopamine lesioned Parkinson's rats
por: Zhang, SuFang, et al.
Publicado: (2014)

Long-term Levodopa Treatment Accelerates the Circadian Rhythm Dysfunction in a 6-hydroxydopamine Rat Model of Parkinson's Disease
por: Li, Si-Yue, et al.
Publicado: (2017)

Cognitive-Enhancing Effect of Quercetin in a Rat Model of Parkinson's Disease Induced by 6-Hydroxydopamine
por: Sriraksa, Napatr, et al.
Publicado: (2012)

Treadmill exercise alleviates short-term memory impairment in 6-hydroxydopamine-induced Parkinson’s rats
por: Cho, Han-Sam, et al.
Publicado: (2013)

Expression of Tgfβ1 and Inflammatory Markers in the 6-hydroxydopamine Mouse Model of Parkinson’s Disease
por: Haas, Stefan Jean-Pierre, et al.
Publicado: (2016)

Impaired Voluntary Wheel Running Behavior in the Unilateral 6-Hydroxydopamine Rat Model of Parkinson's Disease
por: Pan, Qi, et al.
Publicado: (2015)

Protective efficacy of P7C3-S243 in the 6-hydroxydopamine model of Parkinson's disease
por: De Jesús-Cortés, Héctor, et al.
Publicado: (2015)

GDNF Receptor Agonist Alleviates Motor Imbalance in Unilateral 6-Hydroxydopamine Model of Parkinson’s Disease
por: Renko, Juho-Matti, et al.
Publicado: (2020)

Changes in the Neuronal Architecture of the Hippocampus in a 6-Hydroxydopamine-Lesioned Rat Model of Parkinson Disease
por: Kim, Bohye, et al.
Publicado: (2022)

Piracetam and vinpocetine ameliorate rotenone-induced Parkinsonism in rats
por: Zaitone, Sawsan A., et al.
Publicado: (2012)

Excessive levels of nitric oxide in rat model of Parkinson’s disease induced by rotenone
por: XIONG, ZHONG-KUI, et al.
Publicado: (2015)

Involvement of Akt/mTOR in the Neurotoxicity of Rotenone-Induced Parkinson’s Disease Models
por: Zhang, Yu, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_tugadmbadbasv4coblaruveguu